Selected Grants
A Randomized, Controlled, Multicenter, Phase 3 Clinical Study Comparing Vusolimogene Oderparepvec in Combination with Nivolumab Versus Treatment of Physician's Choice in Patients with Advanced Melanoma That Has Progressed on an Anti-PD-1 and an Anti
Clinical TrialPrincipal Investigator · Awarded by Replimune, Inc. · 2024 - 2029Duke Research Training Program in Surgical Oncology
Inst. Training Prgm or CMEMentor · Awarded by National Institutes of Health · 2024 - 2029An Open-Label, Randomized, Controlled Multi-Center Study of the Efficacy of Daromun (L19IL2+L19TNF) Neoadjuvant Intratumoral Treatment Followed by Surgery and Adjuvant Therapy Versus Surgery and Adjuvant Therapy in Clinical Stage IIIB/C Melanoma Pati
Clinical TrialPrincipal Investigator · Awarded by Philogen S.p.A · 2022 - 2027An Open-Label Expanded Access Study of the Melphalan/Hepatic Delivery System (HDS) in Patients with Hepatic Dominant Ocular Melanoma
Clinical TrialPrincipal Investigator · Awarded by Delcath Systems, Inc. · 2022 - 2027U.S. Retrospective Collaborative Study of Melanoma Patients receiving Immune Checkpoint Therapy; "Real World Study"
ResearchPrincipal Investigator · Awarded by Bristol-Myers Squibb Company · 2024 - 2027A prospective registry study of a primary melanoma gene-signature to predict sentinel node (SN) status and determine its prognostic value for more accurate staging of SN-negative melanoma patients
Clinical TrialPrincipal Investigator · Awarded by SkylineDx · 2022 - 2027Improving decision-making for older adults with melanoma
ResearchCollaborator · Awarded by National Institutes of Health · 2024 - 2026Detecting missed metastases from nominally early-stage melanomas with pump-probe microscopy
ResearchCo Investigator · Awarded by United States Army Medical Research Acquisition Activity · 2023 - 2026Beyond tumor staging: measuring immune status at initial diagnosis to detect and prevent melanoma recurrence
ResearchPrincipal Investigator · Awarded by Department of Defense · 2023 - 2026The frequency and function of Type 3 Innate Lymphoid Cells regulates the melanoma tumor microenvironment
FellowshipCo-Mentor · Awarded by National Institutes of Health · 2024 - 2026Replimune RPL-001-16
Clinical TrialPrincipal Investigator · Awarded by Replimune Group, INC · 2021 - 2026CMP-001-011
Clinical TrialPrincipal Investigator · Awarded by Checkmate Pharmaceuticals · 2020 - 2026Checkmate CMP-001-010
Clinical TrialPrincipal Investigator · Awarded by Checkmate Pharmaceuticals · 2020 - 2026Improving Accuracy of Next-Generation Microscopy for Early Stage Metastatic Melanoma Detection
ResearchCollaborator · Awarded by National Institutes of Health · 2024 - 2025Modulation of tumor microenvironment to hinder cancer progression and therapeutic resistance
ResearchCo Investigator · Awarded by Department of Defense · 2022 - 2025Overcoming Anti-PD-1 Resistance in Melanoma by Targeting Immunologic Mediators of the Gli2 Pathway
ResearchCollaborator · Awarded by The Melanoma Research Foundation · 2022 - 2025Investigating the Role of a Novel Dendritic Cell Subset within Sentinel Lymph Node Tissues in Immune Evasion and Melanomagenesis
ResearchCo Investigator · Awarded by Department of Defense · 2021 - 2025Training Program in Bioinformatics at the Intersection of Cancer Immunology and Microbiome
ResearchCollaborator · Awarded by National Cancer Institute · 2020 - 2025PVSRIPO in melanoma
ResearchPrincipal Investigator · Awarded by National Cancer Institute · 2020 - 2025Clinical Biomarker Study of the Tumor NLRP3 Inflammasome and its Role in Anti-PD-1 Immunotherapy Resistance
ResearchCo Investigator · Awarded by Conquer Cancer Foundation · 2021 - 2024OMS-I103 / PICSES
Clinical TrialPrincipal Investigator · Awarded by OncoSec Medical · 2020 - 2024A Randomized, Controlled, Phase 3 Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Melphalan/HDS Treatment in Patients with Hepatic-Dominant Ocular Melanoma
Clinical TrialPrincipal Investigator · Awarded by Delcath Systems, Inc. · 2016 - 2023A Phase I trial of PVSRIPO for Patients with Unresectable Melanoma
Clinical TrialPrincipal Investigator · Awarded by Istari Oncology · 2018 - 2022Tumor draining lymph node B cells as regulators of melanoma progression
ResearchCo Investigator · Awarded by Department of Defense · 2020 - 2021Comprehensive immunologic profiling of the sentinel node to optimize care for patients with melanoma
ResearchPrincipal Investigator · Awarded by Society of Surgical Oncology · 2019 - 2020External Relationships
- Bristol Myers Squibb
This faculty member (or a member of their immediate family) has reported outside activities with the companies, institutions, or organizations listed above. This information is available to institutional leadership and, when appropriate, management plans are in place to address potential conflicts of interest.